FMISO as a Biomarker for Clinical Radiation Oncology.
Tumour hypoxia is a well-known negative prognostic marker in almost all solid tumours. [18F]Fluoromisonidazole (FMISO)-positron emission tomography (PET) is a non-invasive method to detect tumour hypoxia. Compared to other methods of hypoxia assessment it possesses some considerable advantages: It is non-invasive, it delivers spatial information on the hypoxia distribution within the entire tumour volume, and it can be repeated during the course of radio(chemo)therapy. This chapter briefly describes different methods of hypoxia evaluation and focuses on hypoxia PET imaging, with the most commonly used tracer being FMISO. The preclinical rationale and clinical studies to use FMISO-PET for patient stratification in radiation therapy are discussed as well as possible agents or radiation-dose modifications to overcome hypoxia.
OncoRay - National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. Sebastian.Zschaeck@uniklinikum-dresden.de.|German Cancer Consortium (DKTK), Dresden, Germany. Sebastian.Zschaeck@uniklinikum-dresden.de.|German Cancer Research Center (DKFZ), Heidelberg, Germany. Sebastian.Zschaeck@uniklinikum-dresden.de.|Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. Sebastian.Zschaeck@uniklinikum-dresden.de.
Sebastian
S
Zschaeck
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Jörg
J
Steinbach
OncoRay - National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.|German Cancer Consortium (DKTK), Dresden, Germany.|German Cancer Research Center (DKFZ), Heidelberg, Germany.|Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.|Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Esther G C
EG
Troost
D000818:Animals; D006801:Humans; D000860:Hypoxia; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000532:radiotherapy; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D018787:Radiation Oncology / Q000379:methods; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics
D011838:Radiation-Sensitizing Agents; D019275:Radiopharmaceuticals; C031843:fluoromisonidazole; D008920:Misonidazole
FMISO; Hypoxia; PET; Positron emission tomography; [18F]Fluoromisonidazole